operations was THB 1,208 mn, an increase of 10.1% YoY (for 4Q18, the figure stood at THB 370 mn, an increase of 27.6% YoY). The increase is largely attributed to the change in service charge recognition for
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
Consolidated financial statements Change Increase/(Decrease) For Three Months Period Ended 30 September 2017 2018 THB mm % THB mm % THB mm % Sale Revenue Revenue from selling product under Company’s trademark 1
–2021 Balance by Quarter Change Q2–21 Q1–21 Q2–20 Q2–21 VS Q1–21 Q2–21 VS Q2–20 (Million Baht: MB) (MB) % (MB) % Total revenue 2,081.2 1,824.2 1,187.6 257.0 14.1 893.6 75.2 Total operating expenses
2020. 6. Authorised the Chairman of the Board of Executive Directors and/or any person authorised by the Chairman of the Board of Executive Directors to consider any change on date, time and venue
Compact • SASB: Sustainability Accounting Standard Board • CDP: Carbon Disclosure Project • TCFD: Task Force on Climate-Related Financial Disclosure 2023 Rating • AA rating on MSCI ESG ratings • Member of
ประกาศสำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์ (UNOFFICIAL TRANSLATION) Readers should be aware that only the original Thai text has legal force, and that this English translation is
Notification of the Securities and Exchange Commission (UNOFFICIAL TRANSLATION) Readers should be aware that only the original Thai text has legal force and that this English translation is strictly